5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.82▼ | 0.81▼ | 0.79▼ | 0.86▼ | 1.03▼ |
MA10 | 0.80▼ | 0.78▼ | 0.77▲ | 0.99▼ | 1.18▼ |
MA20 | 0.78▲ | 0.77▲ | 0.79▼ | 1.02▼ | 1.32▼ |
MA50 | 0.85▼ | 0.94▼ | 1.01▼ | 1.20▼ | 1.29▼ |
MA100 | 1.05▼ | 1.13▼ | 1.17▼ | 1.28▼ | 1.53▼ |
MA200 | 1.17▼ | 1.23▼ | 1.30▼ | 1.30▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.013▲ | 0.020▲ | 0.018▲ | -0.025▼ | -0.056▼ |
RSI | 44.235▼ | 41.624▼ | 39.324▼ | 28.771▼ | 36.700▼ |
STOCH | 89.303▲ | 73.538 | 56.243 | 29.807 | 16.411▼ |
WILL %R | -64.179 | -54.707 | -54.707 | -85.417▼ | -94.553▼ |
CCI | -8.131 | 30.791 | 32.004 | -136.246▼ | -149.083▼ |
Wednesday, April 30, 2025 11:53 AM
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fib ...
|
Wednesday, April 30, 2025 05:11 AM
Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a ...
|
Wednesday, April 30, 2025 04:33 AM
Silo Pharma, Inc. (NASDAQ:SILO) on Wednesday released results for its preclinical study evaluating SP-26. SP-26 is a ketamine-based injectable dissolvable polymer implant for chronic pain and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 0.74 | 0.87 | 0.7301 | 0.78 | 276,546 |
30/04/25 | 0.77 | 0.80 | 0.71 | 0.75 | 997,300 |
29/04/25 | 0.822 | 0.822 | 0.8001 | 0.8026 | 350,185 |
28/04/25 | 1.10 | 1.15 | 0.839 | 0.84 | 1,049,600 |
25/04/25 | 1.13 | 1.168 | 1.12 | 1.15 | 47,200 |
24/04/25 | 1.18 | 1.18 | 1.13 | 1.14 | 16,500 |
23/04/25 | 1.10 | 1.19 | 1.10 | 1.16 | 21,200 |
22/04/25 | 1.05 | 1.15 | 1.05 | 1.125 | 14,900 |
21/04/25 | 1.04 | 1.08 | 1.04 | 1.06 | 23,600 |
17/04/25 | 1.034 | 1.09 | 1.03 | 1.075 | 13,600 |
|
|
||||
|
|
||||
|
|